EP300 and neoplasm: While control shRNA-infected cells maintained a proliferative rate similar to their untreated counterparts, p300-depleted cells showed a gradual reduction in their proliferation ability, which reached 70–75% at day 7, confirming the marked dependency of these tumor cells on p300 activity (Figure 4C).